Revolutionizing Biopharma: GVSAP and Biocytogen Expand Strategic Collaboration

GV Safety Assessment Platform extends its collaboration with Biocytogen, enhancing access to advanced research tools for India's biopharma sector. The partnership now includes pharmacology services and gene-edited cell line distribution, which accelerates preclinical research and supports drug innovation. GVSAP aims to position India as a leader in global preclinical innovation.

The GV Safety Assessment Platform (GVSAP) has announced a significant expansion of its partnership with global biotechnology firm Biocytogen. The collaboration aims to provide Indian biopharma researchers with enhanced tools for drug discovery.

The alliance now includes streamlined pharmacology services and licensing of gene-edited cell lines, significantly cutting preclinical screening times. This move supports India's burgeoning biopharma ecosystem, allowing for seamless research workflows from target validation to pharmacological evaluation.

Headquartered in Genome Valley, Hyderabad, GVSAP's state-of-the-art facilities ensure the highest standards in research integrity, with a focus on biosafety and animal welfare. This collaboration aims to position India as a global hub for preclinical research and pharmaceutical innovation.

(With inputs from agencies.)